APC & METTLER TOLEDO Announce Partnership to Advance Digitalization in Pharma Development
DUBLIN | 23 June, 2025 – APC, part of The Medicine Accelerator—a pioneering Irish multinational group comprising APC and its sister company VLE Therapeutics—has been at the forefront of CMC digitalization since 2019. Through innovations like the AI-powered iAchieve® platform and a commitment to integrating live data with expert-led design, APC has redefined pharmaceutical development, enabling faster, smarter pathways from concept to clinic.
Building on this foundation, APC announces a strategic partnership with METTLER TOLEDO AutoChem, a global leader in automated reactor technology, process analytical tools (PAT), and chemical development software platforms. This collaboration aims to extend APC’s digital-first approach into the physical realm by integrating advanced, cutting-edge technologies and sophisticated modeling tools. Together, the partnership seeks to build a fully integrated digital development environment—advancing how data, decisions, and design converge across the full CMC lifecycle.
The announcement coincides with APC and VLE Therapeutics' €100 million investment in The Medicine Accelerator Campus, a 130,000 sq. ft. state-of-the-art facility in Cherrywood, Dublin. This expansion will add 300 new jobs, reinforcing Ireland's position as a global hub for pharmaceutical innovation. The campus embodies the group’s commitment to integrating best-in-class science with first-in-class digital solutions, transforming how medicines are researched, digitized, and manufactured.
Revolutionizing Medicine Development
This partnership integrates APC’s expertise in process development, CMC (Chemistry, Manufacturing, and Controls), and GMP (Good Manufacturing Practices) with METTLER TOLEDO’s precision automation and process analytical technologies. Together, the two companies aim to accelerate medicine development through:
Advanced Digital Solutions: Leveraging AI-powered platforms like APC’s iAchieve and METTLER TOLEDO’s iC and Scale-up Systems software platforms to digitize development and enable seamless scalability.
Data-Driven Insights: Combining APC’s deep process expertise with METTLER TOLEDO’s cutting-edge measurement technologies to deliver unprecedented process understanding, optimization, and control. Benefits include AI-driven particle tracking and image analysis, advanced reaction engineering for digital step design, and integrated web applications—such as iAchieve and the iC suite—to streamline workflows.
Industry-Leading Science: Jointly offering enhanced solutions for pharmaceutical manufacturers navigating the challenges of drug development and commercialization.
Agentic Intelligence and digital knowledge management are reshaping the pharmaceutical industry, and our partnership with METTLER TOLEDO brings this vision to life,” said Mark Barrett, CEO of APC and VLE Therapeutics. “By combining our world-class scientists, AI-powered platforms, and METTLER TOLEDO technologies, we’re creating a future where medicine development is faster, more predictable, and more accessible.
Positive health outcomes rely on a number of key factors, including the continual development of novel medicines and therapeutics,” said Kumud Goyal, Head of METTLER TOLEDO AutoChem. “Efficient process development is an essential driver of those outcomes. Our partnership with APC will continue to push these boundaries through greater data insights, advanced models for efficient development, and safe, reliable scale-up processes. Our products are trusted by scientists across the pharmaceutical and chemical industries, and by working with APC, we look forward to delivering even greater efficiency in drug development.
Driving Collaboration for Global Impact
This strategic partnership with METTLER TOLEDO underscores APC’s leadership in fostering innovation at the intersection of digitalization and pharmaceutical R&D. It builds on APC’s established track record of partnering with eight of the top 10 global pharmaceutical companies and driving advancements across more than 35 medicines, including therapies for oncology, Alzheimer’s, and respiratory diseases.
This partnership is a transformative opportunity for the pharmaceutical industry,” said Mark Barrett, CEO of APC and VLE Therapeutics. “By aligning our strengths, we’re reimagining the future of medicine development.”
About APC
APC, headquartered in Dublin, Ireland, is a leader in pharmaceutical process research and development, pioneering innovations in CMC, GMP, and digitalization. Through partnerships with global pharmaceutical and biotech companies, APC accelerates medicine development and manufacturing to deliver better patient outcomes.
About METTLER TOLEDO
METTLER TOLEDO is a global leader in precision instruments and services. We are renowned for innovation and quality across laboratory, process analytics, industrial, product inspection, and retailing applications. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries, and we have a direct presence in approximately 40 countries. For more information, please visit www.mt.com.
For media inquiries, contact: [email protected]